Myriad Genetics (MYGN) shares were down more than 6% in Tuesday trading after Piper Sandler downgraded the stock to underweight from overweight.
Trading volume stood at more than 1.4 million shares, compared with a daily average of about 1.8 million.
Price: $3.02, Change: $-0.21, Percent Change: -6.37%